Clinical trial · Interventional
Circulating Tumor Cells and mpMRI for Non-invasive Diagnosis of Prostate Cancer(CMNDPC)
A Prospective Multicenter Cohort Study for Non-invasive Diagnosis of Prostate Cancer: In Vivo Isolation of Circulating Tumor Cells Plus Multimodal MRI
NCT05947188CI-TRIAL-00073607CMNDPCunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial is a prospective, multicentre, diagnostic study. This study aims to evaluation the early diagnostic ability of circulating tumor cells plus multimodal MRI for prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| prostate cancer diagnosis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Sample for Circulating Tumoral Cells
- description
- Sampling of Circulating Tumoral Cells will be done
- interventionNames
- Other: prostate cancer diagnosis
Primary outcomes (1)
- measure
- Positive predictive value of CTCs counts for prostate cancer
- timeFrame
- 12 weeks
- description
- Evaluation the diagnostic ability of CTCs counts in caner and non-cancer. All patients were confirmed by pathology.
Secondary outcomes (2)
- measure
- Correlation between CTCs counts and PIRADS score
- timeFrame
- 12 weeks
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 50 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. No family history of prostate cancer; 2. men ≥ 50 years； 3. tPSA level of 4-10 ng/ml, and fPSA/tPSA\<0.16; 4. tPSA level of \>10 ng/ml； 5. With abnomal mpMRI、PET/CT、TRUS or DRE; 6. fully understand the clinical trial protocol and sign the informed consent; Exclusion Criteria: 1. Not meet all of the inclusion criteria or any single inclusion criteria； 2. previous diagnosis of prostate carcinoma ; 3. symptomatic of acute prostatitis; 4. local anesthetic allergy patients; 5. cannot tolerate prostate biopsy or has contraindication to biopsy; 6. patients judged by the investigator to be unsuitable to participate in the clinical trial;
References
Publications (0)
Data not yet available
No reference posted for this study.